Chardan Capital Maintains Buy on Arrowhead Pharma, Raises Price Target to $115
Benzinga Newsdesk 3 months ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $90 to $115.
Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma (NASDAQ:ARWR) with a Buy and raises the price target from $90 to $115.